Caris Life Sciences (CAI) Income towards Parent Company (2024 - 2026)

Caris Life Sciences' Income towards Parent Company history runs 3 years deep, the most recent figure standing at -$510000.0 for Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 99.5% year-over-year to -$510000.0 in Q1 2026; TTM through Mar 2026 was $34.0 million, a 112.43% increase from a year earlier, with the FY2025 full-year figure at -$68.1 million, up 75.85% from the prior year.
• Income towards Parent Company slipped to -$510000.0 in Q1 2026 per CAI's latest filing, from $82.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $82.0 million in Q4 2025 and bottomed at -$102.6 million in Q1 2025.
• The 3-year median for Income towards Parent Company is -$51.6 million (2024), against an average of -$29.9 million.
• Biggest YoY gain for Income towards Parent Company was 321.82% in 2025; the steepest drop was 8.47% in 2025.
• Year by year, Income towards Parent Company stood at -$36.9 million in 2024, then soared by 321.82% to $82.0 million in 2025, then tumbled by 100.62% to -$510000.0 in 2026.
• Per Business Quant, the three latest CAI Income towards Parent Company figures stand at -$510000.0 (Q1 2026), $82.0 million (Q4 2025), and $24.3 million (Q3 2025).